Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | PRNP | P04156 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1879067 | 1.00 | MAPT (0.49) | MAPTMEN1KMT2ASMN1; SMN2THRB | |
| SCHEMBL12672203 | 0.89 | MAPT (0.51) | MAPTMEN1KMT2ASMN1; SMN2THRB | |
| SCHEMBL1888032 | 0.88 | CYP1A2 (0.51) | MAPTMEN1KMT2ASMN1; SMN2THRB | |
| SCHEMBL1886649 | 0.87 | MAPT (0.53) | MAPTMEN1KMT2ASMN1; SMN2THRB | |
| SCHEMBL15189106 | 0.86 | ALDH1A1 (0.51) | MAPTMEN1KMT2ASMN1; SMN2THRB | |
| SCHEMBL15189209 | 0.86 | MAPT (0.54) | MAPTMEN1KMT2ASMN1; SMN2THRB | |
| SCHEMBL1568589 | 0.86 | MAPT (0.54) | MAPTMEN1KMT2ASMN1; SMN2THRB | |
| SCHEMBL12639366 | 0.86 | ALDH1A1 (0.49) | MAPTMEN1KMT2ASMN1; SMN2THRB | |
| SCHEMBL12672209 | 0.86 | TDP1 (0.54) | MAPTMEN1KMT2ASMN1; SMN2THRB | |
| SCHEMBL12639393 | 0.85 | MAPT (0.48) | MAPTMEN1KMT2ASMN1; SMN2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519188-B2 | Compounds which can be used for the treatment of cancers | Marc-Henry Pitty (FR) | 2013-08-27 | — | — | US | disclosed |
| US-8519188-B2 | Compounds which can be used for the treatment of cancers | Marc-Henry Pitty (FR) | 2013-08-27 | — | — | US | disclosed |
| US-8519188-B2 | Compounds which can be used for the treatment of cancers | Marc-Henry Pitty (FR) | 2013-08-27 | — | — | US | disclosed |
| EP-2307017-B1 | COMPOUNDS WHICH CAN BE USED FOR THE TREATMENT OF CANCERS | PITTY MARC HENRY (FR) | 2013-08-14 | — | — | EP | disclosed |
| EP-2307017-B1 | COMPOUNDS WHICH CAN BE USED FOR THE TREATMENT OF CANCERS | PITTY MARC HENRY (FR) | 2013-08-14 | — | — | EP | disclosed |
| US-20110104162-A1 | Compounds which can be used for the Treatment of Cancers | CYTOMICS SYSTEMS (FR) | 2011-05-05 | — | — | US | disclosed |
| US-20110104162-A1 | Compounds which can be used for the Treatment of Cancers | CYTOMICS SYSTEMS (FR) | 2011-05-05 | — | — | US | disclosed |
| US-20110104162-A1 | Compounds which can be used for the Treatment of Cancers | CYTOMICS SYSTEMS (FR) | 2011-05-05 | — | — | US | disclosed |
| WO-2009150248-A1 | COMPOUNDS WHICH CAN BE USED FOR THE TREATMENT OF CANCERS | CYTOMICS SYSTEMS (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104162-A1 | Compounds which can be used for the Treatment of Cancers | VHL, CYP11B2, SLC10A1 | MAPT 2578/4885MEN1 70/4885KMT2A 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.